Management of Acute Rejection in Kidney Transplant Patients

Immediate Management of Acute Rejection

The American College of Radiology recommends performing a kidney allograft biopsy before initiating rejection treatment to confirm the diagnosis and rule out other causes, unless the biopsy would substantially delay therapy 1, 3
The Kidney International guidelines suggest initiating high-dose corticosteroids as first-line treatment for biopsy-confirmed acute cellular rejection, regardless of which calcineurin inhibitor the patient is receiving 1, 2
Adding or restoring maintenance prednisone to the immunosuppressive regimen is recommended if the patient was not already on maintenance steroids, as the occurrence of rejection indicates inadequate immunosuppression 1, 2
Verifying tacrolimus trough levels are therapeutic (typically 5-15 ng/mL in the early post-transplant period) is crucial, as subtherapeutic levels may have contributed to the rejection episode 1, 5

Changing calcineurin inhibitors during active rejection introduces unnecessary risk of unstable immunosuppression during a critical period when the graft is already under immune attack 1
Both tacrolimus and cyclosporine require time to reach steady-state levels (typically 3-5 days), creating a window of subtherapeutic immunosuppression during conversion that could worsen rejection 6
Conversion from tacrolimus to cyclosporine may be considered after successful reversal of rejection, in specific scenarios such as steroid-resistant rejection, documented tacrolimus nephrotoxicity, or intolerable tacrolimus-specific side effects 1, 2, 6

Monitoring cyclosporine trough levels every other day until stable therapeutic targets are reached (typically 200-300 ng/mL in early post-transplant period) is essential during the conversion period 1, 6
Measuring serum creatinine 2-3 times per week during the conversion period can help detect any decline in kidney function 1
Performing repeat biopsy if creatinine rises or does not stabilize within 2 weeks of conversion can help rule out ongoing rejection or new calcineurin inhibitor toxicity 1, 2

Reducing overall immunosuppression intensity during or immediately after rejection is not recommended, as the rejection itself indicates the patient requires more, not less, immunosuppression 2
Switching calcineurin inhibitors without addressing the rejection first with corticosteroids can delay appropriate treatment and risk graft loss 1, 2
Assuming prior tolerance to cyclosporine guarantees current tolerance is not advisable, as the patient's immune status and graft condition have changed since the previous transplant 6
Avoiding generic substitutions during conversion without intensive monitoring is recommended, as bioequivalence issues can lead to subtherapeutic levels and precipitate further rejection 1, 6